Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications
作者： H. Derendorf , E. O. Meltzer
DOI: 10.1111/J.1398-9995.2008.01750.X
关键词: Triamcinolone acetonide 、 Fluticasone 、 Corticosteroid 、 Nasal administration 、 Flunisolide 、 Immunology 、 Pharmacology 、 Budesonide 、 Mometasone furoate 、 Fluticasone propionate 、 Medicine 、 Immunology and Allergy
摘要: … moiety in the later compound is the same as that found in the mometasone furoate molecule, ie fluticasone furoate is fluticasone propionate with the furoate ester of mometasone furoate…
sci-hub.se 参考文章(55)
Joseph Bikowski, Radhakrishnan Pillai, Braham Shroot, The position not the presence of the halogen in corticosteroids influences potency and side effects. Journal of Drugs in Dermatology. ,vol. 5, pp. 125- 130 ,(2006)
Kreutner W, Smith Cl, In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Drug Research. ,vol. 48, pp. 956- ,(1998)
Edward E. Philpot, Eli O. Meltzer, Melissa A. Faris, Robert F. Lemanske, Kathleen A. Rickard, David B. Allen, Kenneth M. Kral, Barbara A. Prillaman, No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy and asthma proceedings : the official journal of regional and state allergy societies. ,vol. 23, pp. 407- 413 ,(2002)
Lenczewska D, Buko Z, Południewska B, Rogalewska Am, Chyrek-Borowska S, [The efficacy of a new medication -- intranasal glucocorticoid mometasone furoate (Nasonex) -- in seasonal allergic rhinitis]. The Polish otolaryngology. ,vol. 52, pp. 181- ,(1998)
H. König, H. Ponta, H.J. Rahmsdorf, P. Herrlich, Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo. The EMBO Journal. ,vol. 11, pp. 2241- 2246 ,(1992) , 10.1002/J.1460-2075.1992.TB05283.X
Hartmut Derendorf, Guenther Hochhaus, What is the best marker for inhaled corticosteroid safety Allergy and asthma proceedings : the official journal of regional and state allergy societies. ,vol. 26, pp. 89- 93 ,(2005)
E. Dahlberg, Jan-Ake Gustafsson, T. Saartok, K. Roempke, U. Johansson, A. Thalen, R. Brattsand, Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Molecular Pharmacology. ,vol. 25, pp. 70- 78 ,(1984)
A. W. McKENZIE, Percutaneous Absorption of Steroids Archives of Dermatology. ,vol. 86, pp. 611- 614 ,(1962) , 10.1001/ARCHDERM.1962.01590110047006
Maria G. Belvisi, Daniela S. Bundschuh, Michael Stoeck, Sharon Wicks, Stephen Underwood, Clifford H. Battram, El-Bdaoui Haddad, Stephen E. Webber, Martyn L. Foster, Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma Journal of Pharmacology and Experimental Therapeutics. ,vol. 314, pp. 568- 574 ,(2005) , 10.1124/JPET.105.085217
O. D. Wolthers, S. Pedersen, Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy. ,vol. 49, pp. 96- 99 ,(1994) , 10.1111/J.1398-9995.1994.TB00807.X